Current Oncology, Free Full-Text
By A Mystery Man Writer
Description
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
🔍 Sneak Peek into the Future! 🚀✨ Introducing our Program for
Advances in Radiation Oncology, Journal
How A.I. Is Being Used to Detect Cancer That Doctors Miss - The
Current Oncology, Free Full-Text
Journal of Current Oncology - Free full text articles from Journal of Current Oncology
Current Oncology, Free Full-Text
Current Oncology, Free Full-Text
PDF) Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer
HealthXL Reports - Oncology Community Report
What is secondary lung cancer?
Current Oncology, Free Full-Text
from
per adult (price varies by group size)